Commissioner Byrne sees devices playing key role as European Commission ages
This article was originally published in Clinica
Constant innovation in medical technologies and techniques is the main factor driving increases in health expenditure. That is the conclusion of the European Commission, which has stated its commitment to ensuring that as innovations are introduced, their efficiency and effectiveness are properly evaluated in comparison to existing practices to ensure evidence-based medical practice.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.